ALLO
USDAllogene Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.200
High
$1.210
Low
$1.170
Volume
4.81M
Company Fundamentals
Market Cap
260.3M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
3.10M
Exchange
NMS
Currency
USD
52-Week Range
Related News
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)
Citigroup Maintains Buy on Allogene Therapeutics, Lowers Price Target to $4
Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics with a Buy and lowers the price target from $8 to $4.
Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $10
Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics with a Buy and lowers the price target from $14 to $10.
Piper Sandler Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $7
Piper Sandler analyst Biren Amin maintains Allogene Therapeutics with a Overweight and lowers the price target from $9 to $7.
RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target
RBC Capital analyst Luca Issi reiterates Allogene Therapeutics with a Outperform and maintains $10 price target.
Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $9
Oppenheimer analyst Matthew Biegler maintains Allogene Therapeutics with a Outperform and lowers the price target from $10 to $9.
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.